Cargando…
Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc(3+) and Y(3+) and characterize fundamental meta...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814396/ https://www.ncbi.nlm.nih.gov/pubmed/36703424 http://dx.doi.org/10.1038/s42004-020-0307-0 |
_version_ | 1784864123624882176 |
---|---|
author | Carter, Korey P. Deblonde, Gauthier J.-P. Lohrey, Trevor D. Bailey, Tyler A. An, Dahlia D. Shield, Katherine M. Lukens, Wayne W. Abergel, Rebecca J. |
author_facet | Carter, Korey P. Deblonde, Gauthier J.-P. Lohrey, Trevor D. Bailey, Tyler A. An, Dahlia D. Shield, Katherine M. Lukens, Wayne W. Abergel, Rebecca J. |
author_sort | Carter, Korey P. |
collection | PubMed |
description | The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc(3+) and Y(3+) and characterize fundamental metal–chelator binding interactions in solution via UV-Vis spectrophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc(3+) and Y(3+) binding with 343-HOPO is found to be robust, with both high thermodynamic stability and fast room temperature radiolabeling, indicating that 343-HOPO is likely a promising chelator for in vivo applications with both metals. As a proof of concept, we prepared a (86)Y-343-HOPO complex for in vivo PET imaging, and the results presented herein highlight the potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic applications. |
format | Online Article Text |
id | pubmed-9814396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98143962023-01-10 Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals Carter, Korey P. Deblonde, Gauthier J.-P. Lohrey, Trevor D. Bailey, Tyler A. An, Dahlia D. Shield, Katherine M. Lukens, Wayne W. Abergel, Rebecca J. Commun Chem Article The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc(3+) and Y(3+) and characterize fundamental metal–chelator binding interactions in solution via UV-Vis spectrophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc(3+) and Y(3+) binding with 343-HOPO is found to be robust, with both high thermodynamic stability and fast room temperature radiolabeling, indicating that 343-HOPO is likely a promising chelator for in vivo applications with both metals. As a proof of concept, we prepared a (86)Y-343-HOPO complex for in vivo PET imaging, and the results presented herein highlight the potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic applications. Nature Publishing Group UK 2020-05-15 /pmc/articles/PMC9814396/ /pubmed/36703424 http://dx.doi.org/10.1038/s42004-020-0307-0 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Carter, Korey P. Deblonde, Gauthier J.-P. Lohrey, Trevor D. Bailey, Tyler A. An, Dahlia D. Shield, Katherine M. Lukens, Wayne W. Abergel, Rebecca J. Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title | Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title_full | Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title_fullStr | Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title_full_unstemmed | Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title_short | Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
title_sort | developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814396/ https://www.ncbi.nlm.nih.gov/pubmed/36703424 http://dx.doi.org/10.1038/s42004-020-0307-0 |
work_keys_str_mv | AT carterkoreyp developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT deblondegauthierjp developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT lohreytrevord developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT baileytylera developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT andahliad developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT shieldkatherinem developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT lukenswaynew developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals AT abergelrebeccaj developingscandiumandyttriumcoordinationchemistrytoadvancetheranosticradiopharmaceuticals |